Robin Matsukawa, MD
Internal Medicine · Kaneohe, HINPI 1568668325
Payments from drug & device makers
Across 46 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$319
- Lilly USA, LLC$187
- AstraZeneca$139
- GSK$62
- Amgen$59
- Boehringer Ingelheim$46
- plus $240 from 8 others
What the payments were for
- Food & beverage$91987%
- Education$13213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $319 |
| Lilly USA, LLC | 9 | $187 |
| AstraZeneca | 7 | $139 |
| GSK | 3 | $62 |
| Amgen | 3 | $59 |
| Boehringer Ingelheim | 2 | $46 |
| Exact Sciences | 2 | $43 |
| Pfizer | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Gilead | 1 | $30 |
| Bayer | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$1,051 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 127 | $162,757 |
| JardianceEmpagliflozin | 81 | $122,264 |
| OzempicSemaglutide | 66 | $119,397 |
| RybelsusSemaglutide | 40 | $83,457 |
| MounjaroTirzepatide | 36 | $67,600 |
| TrulicityDulaglutide | 39 | $62,961 |
| EliquisApixaban | 36 | $45,891 |
| JanuviaSitagliptin Phosphate | 19 | $30,363 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $28,651 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $22,677 |
| Atorvastatin Calcium | 827 | $21,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,458 |
| TradjentaLinagliptin | 16 | $17,787 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $17,760 |
| Rosuvastatin Calcium | 348 | $16,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $319 | $202,853106 claims |
| AstraZenecaFarxiga | $139 | $162,757127 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $46 | $147,550112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $187 | $130,56175 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $62 | $53,11255 claims |
| PfizerEliquis | $37 | $45,89136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Kaneohe
- Mark LeeKaneohe$18K
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.